Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 2, 2011, Pages 344-355

  Chen, Chen ^a   Wei, Xin ^a   Rao, Xiaoquan ^a   Wu, Jun ^a   Yang, Shenglan ^a   Chen, Fuqiong ^a   Ma, Ding ^a   Zhou, Jianfeng ^a   Dackor, Ryan T ^b   Zeldin, Darryl C ^b   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (VINYL)PHENYL] 4 [ 4 (DIPHENYLHYDROXYMETHYL)PIPERIDINYL]BUTANONE; ALKANONE; CASPASE 3; CYTOCHROME P450 2J2; CYTOCHROME P450 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPOXYICOSATRIENOIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; LEUKEMIA; MALE; MICE; MICE, INBRED C57BL; RNA, MESSENGER;

EID: 78751558396     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.174805     Document Type: Article

References (39)

1. Bacchiocchi R, Baldanzi G, Carbonari D, Capomagi C, Colombo E, van Blitterswijk WJ, Graziani A, and Fazioli F (2005) Activation of alpha-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase. Blood 106:2175-2182. (Pubitemid 41291736)
2. Boyer MW, Vallera DA, Taylor PA, Gray GS, Katsanis E, Gorden K, Orchard PJ, and Blazar BR (1997) The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. Blood 89:3477-3485.
3. Campàs C, Lopez JM, Santidrián AF, Barragán M, Bellosillo B, Colomer D, and Gil J (2003) Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood 101:3674-3680. (Pubitemid 36857958)
4. Campbell WB and Harder DR (1999) Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 84:484-488.
5. Capdevila JH, Falck JR, and Estabrook RW (1992) Cytochrome P450 and the arachidonate cascade. FASEB J 6:731-736.
6. Chen C, Li G, Liao W, Wu J, Liu L, Ma D, Zhou J, Elbekai RH, Edin ML, Zeldin DC, et al. (2009) Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J Pharmacol Exp Ther 329:908-918.
7. Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros LJ, and Rassidakis GZ (2009) Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia 23:784-790.
8. Elbekai RH and El-Kadi AO (2006) Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 112:564-587.
9. Enayetallah AE, French RA, Thibodeau MS, and Grant DF (2004) Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 52:447-454.
10. Fleming I (2007) Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat 82:60-67.
11. Flotho C, Kratz C, and Niemeyer CM (2007) Targeting RAS signaling pathways in juvenile myelomonocytic leukemia. Curr Drug Targets 8:715-725.
12. Harder DR, Campbell WB, and Roman RJ (1995) Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J Vasc Res 32:79-92.
13. Honma Y (2002) Cotylenin A - a plant growth regulator as a differentiation-inducing agent against myeloid leukemia. Leuk Lymphoma 43:1169-1178.
14. Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN, Ning YG, Xiao X, Zeldin DC, and Wang DW (2005) Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 65:4707-4715.
15. Jiang JG, Ning YG, Chen C, Ma D, Liu ZJ, Yang S, Zhou J, Xiao X, Zhang XA, Edin ML, et al. (2007) Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res 67:6665-6674.
16. Kinjo K, Sandoval S, Sakamoto KM, and Shankar DB (2005) The role of CREB as a proto-oncogene in hematopoiesis. Cell Cycle 4:1134-1135.
17. Kroetz DL and Zeldin DC (2002) Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol 13:273-283. (Pubitemid 34592284)
18. Lafite P, Dijols S, Buisson D, Macherey AC, Zeldin DC, Dansette PM, and Mansuy D (2006) Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2. Bioorg Med Chem Lett 16:2777-2780.
19. Lagadinou ED, Ziros PG, Tsopra OA, Dimas K, Kokkinou D, Thanopoulou E, Karakantza M, Pantazis P, Spyridonidis A, and Zoumbos NC (2008) c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia. Leukemia 22:1899-1908.
20. Larsen BT, Gutterman DD, and Hatoum OA (2006) Emerging role of epoxyeicosatrienoic acids in coronary vascular function. Eur J Clin Invest 36:293-300.
21. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, et al. (2010) Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 24:3770-3781.
22. Lin HK, Bergmann S, and Pandolfi PP (2005) Deregulated TGF-beta signaling in leukemogenesis. Oncogene 24:5693-5700.
23. Markovic A, MacKenzie KL, and Lock RB (2005) FLT-3: a new focus in the understanding of acute leukemia. Int J Biochem Cell Biol 37:1168-1172.
24. Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM, Manzoli L, McCubrey JA, and Cocco L (2007) Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 14:2009-2023.
25. Mikesch JH, Steffen B, Berdel WE, Serve H, and Müller-Tidow C (2007) The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. Leukemia 21:1638-1647.
26. Nishioka C, Ikezoe T, Yang J, and Yokoyama A (2010) Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene. Leukemia 24:1631-1640
27. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285:1276-1279.
28. Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185.
29. Roy S, Bayly CI, Gareau Y, Houtzager VM, Kargman S, Keen SL, Rowland K, Seiden IM, Thornberry NA, and Nicholson DW (2001) Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide. Proc Natl Acad Sci USA 98:6132-6137.
30. Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, Soga S, Murakata C, Tamaoki T, and Akinaga S (2000) Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 96:2284-2291.
31. Spiecker M and Liao JK (2005) Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 433:413-420.
32. Van Etten RA (2007) Aberrant cytokine signaling in leukemia. Oncogene 26:6738-6749.
33. Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, Wang DW, and Zeldin DC (2005) Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther 314:522-532. (Pubitemid 41043832)
34. Wegiel B, Bjartell A, Tuomela J, Dizeyi N, Tinzl M, Helczynski L, Nilsson E, Otterbein LE, Härkönen P, and Persson JL (2008) Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J Natl Cancer Inst 100:1022-1036.
35. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw CR, and Zeldin DC (1997) Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272:12551-12559.
36. Wu S, Moomaw CR, Tomer KB, Falck JR, and Zeldin DC (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460-3468.
37. Yang S, Lin L, Chen JX, Lee CR, Seubert JM, Wang Y, Wang H, Chao ZR, Tao DD, Gong JP, et al. (2007) Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways Am J Physiol Heart Circ Physiol 293:H142-H151.
38. Zeldin DC (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276:36059-36062.
39. Zeldin DC, Foley J, Goldsworthy SM, Cook ME, Boyle JE, Ma J, Moomaw CR, Tomer KB, Steenbergen C, and Wu S (1997) CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance. Mol Pharmacol 51:931-943.